Clarius Group LLC Cuts Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Clarius Group LLC lowered its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,848 shares of the biopharmaceutical company’s stock after selling 175 shares during the period. Clarius Group LLC’s holdings in Gilead Sciences were worth $633,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of GILD. Massachusetts Financial Services Co. MA raised its stake in shares of Gilead Sciences by 0.6% during the second quarter. Massachusetts Financial Services Co. MA now owns 85,804 shares of the biopharmaceutical company’s stock valued at $5,887,000 after acquiring an additional 522 shares during the last quarter. Seven Eight Capital LP purchased a new position in Gilead Sciences during the 2nd quarter valued at about $525,000. MQS Management LLC lifted its holdings in Gilead Sciences by 33.9% in the 2nd quarter. MQS Management LLC now owns 4,573 shares of the biopharmaceutical company’s stock worth $314,000 after buying an additional 1,157 shares during the period. Ieq Capital LLC grew its position in shares of Gilead Sciences by 3.7% in the 2nd quarter. Ieq Capital LLC now owns 69,215 shares of the biopharmaceutical company’s stock worth $4,749,000 after buying an additional 2,453 shares during the last quarter. Finally, Canada Pension Plan Investment Board increased its stake in shares of Gilead Sciences by 91.4% during the second quarter. Canada Pension Plan Investment Board now owns 2,699,863 shares of the biopharmaceutical company’s stock valued at $185,238,000 after buying an additional 1,289,420 shares during the period. Institutional investors own 83.67% of the company’s stock.

Analyst Upgrades and Downgrades

GILD has been the topic of several recent analyst reports. Wolfe Research began coverage on shares of Gilead Sciences in a report on Friday, November 15th. They issued an “outperform” rating and a $110.00 price target on the stock. Maxim Group lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Friday, November 8th. The Goldman Sachs Group increased their price target on shares of Gilead Sciences from $74.00 to $84.00 and gave the stock a “neutral” rating in a research note on Thursday, November 7th. Bank of America reaffirmed a “buy” rating and set a $109.00 price objective on shares of Gilead Sciences in a research report on Tuesday, December 10th. Finally, Mizuho increased their target price on Gilead Sciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a research report on Thursday, November 21st. Eleven equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have issued a strong buy rating to the company. According to MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and a consensus price target of $97.96.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, Director Jeffrey Bluestone sold 6,788 shares of the stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total value of $620,355.32. Following the completion of the sale, the director now owns 8,920 shares in the company, valued at approximately $815,198.80. This represents a 43.21 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Merdad Parsey sold 25,590 shares of the firm’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total value of $2,341,485.00. Following the sale, the insider now directly owns 99,599 shares in the company, valued at approximately $9,113,308.50. This represents a 20.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 456,234 shares of company stock valued at $42,130,461. Company insiders own 0.29% of the company’s stock.

Gilead Sciences Trading Up 0.2 %

Shares of NASDAQ:GILD opened at $91.84 on Friday. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $98.90. The stock has a market capitalization of $114.46 billion, a price-to-earnings ratio of 1,020.44, a PEG ratio of 1.27 and a beta of 0.18. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. The stock’s 50-day simple moving average is $91.75 and its two-hundred day simple moving average is $83.97.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The company had revenue of $7.55 billion during the quarter, compared to analyst estimates of $7.01 billion. During the same period in the previous year, the business posted $2.29 earnings per share. The firm’s quarterly revenue was up 7.0% compared to the same quarter last year. Analysts expect that Gilead Sciences, Inc. will post 4.36 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, December 30th. Investors of record on Friday, December 13th were issued a $0.77 dividend. The ex-dividend date was Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a yield of 3.35%. Gilead Sciences’s dividend payout ratio is currently 3,422.22%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.